Urologie Labor

Publikationen 2020 - 2023

Kang J, La Manna F, Bonollo F, Sampson N, Alberts I L, Mingels C, Afshar-Oromieh A, Thalmann GN, Karkampouna S (2022). Tumor microenvironment mechanisms and bone metastatic disease progression of prostate cancer; Cancer Lett 530: 156-169.
Furlan T, Kirchmair A, Sampson N, Puhr M, Gruber M, Trajanoski Z, Santer FR, Parson W, Handle F, Culig Z (2021). MYC-mediated ribosomal gene expression sensitizes enzalutamide-resistant prostate cancer cells to EP300/CREBBP inhibitors; Am J Pathol 191: 1094-1107
Gruber M, Ferrone L, Puhr M, Santer FR, Fulran T, Eder IE, Sampson N, Schäfer G, Handle F, Culig Z (2020). p300 is upregulated by docetaxel and is a target in chemoresistant prostate cancer; Endocr Relat Cancer 27: 187-198.
Gruber M, Handle F, Culig Z (2020). The stem cell inhibitor salinomycin decreases colony formation potential and tumor-initiating population in docetaxel-sensitive and docetaxel-resistant prostate cancer cells; Prostate 80:267-273.
Pichler R, Lindner AK, Comperat E, Obrist P, Schäfer G, Todenhöfer T, Horninger W, Culig Z, Untergasser G (2020). Amplification of 7p12 is associated with pathologic nonresponse to neodjuvant chemotherapy in muscle-invasive bladder cancer; Am J Pathol 190:442-452.
Drapela S, Khisariya P, van Weerden WM, Fedr R, Suchankova T, Buzova D, Cerveny J, Hampl A, Puhr M, Watson WR, Culig Z, Krejci L, Paruch K, Soucek K (2020). The CHK1 inhibitor MU380 significantly increases the sensitivity of human docetaxel-resistant prostate cancer cells to gemcitabine through the induction of mitotic catastrophe; Mol Oncol 14:2487-2503.
Erb HHH, Bodenbender J, Handle F, Diehl T, Donix L, Tsaur I, Gleave M, Haferkamp A, Huber J, Fuessel S, Juengel E, Culig Z, Thomas C (2020). Assessment of STAT5 as a potential therapy target in enzalutamide-resistant prostate cancer; PLoS One 15:e0237248.
Aksoy O, Pencik J, Hartenbach M, Moazzami AA, Schlederer M, Balber T, Varady A, Philippe C, Baltzer PA, Mazumder B, Whitchurch JB, Roberts CJ, Haitel A, Herac M, Susani M, Mitterhauser M, Marculescu R, Stangl-Kremser J, Hassler MR, Kramer G, Shariat SF, Turner SD, Tichy B, Oppelt J, Pospisilova S, Hartenbach S, Tangemann S, Egger G, Neubauer HA, Moriggl R, Culig Z, Greiner G, Hoermann G, Hacker M, Heery DM, Merkel O, Kenner L (2021). Thyroid and androgen receptor signaling are antagonized by CRYM in prostate cancer; Int J Cancer 148:731-747.
Tulchiner G, Staudacher N, Fritz J, Radmayr C, Culig Z, Horninger W, Pichler R (2021). The COVID19 pandemic gap and its influence o.n oncologic outcomes of bladder cancer; Cancers (Basel) 13:1754
Tulchiner G, Brunner A, Schmidinger M, Staudacher N; Orme JJ, Thurnher M, Horninger W, Culig Z, Pichler R (2021). CMTM6 expression as a potential biomarker for immunotherapy in metastatic renal carcinoma; BJU Int 128:29-32.
Erb HHH, Culig Z, Stope MB (2021). IL-4 counteracts the cytotoxic effects of peripheral blood mononuclear cells on hormone-sensitive prostate cancer cells; In Vivo 35:1973-1977.
Offermann A, Kang D, Watermann C, Weingart A, Hupe MC, Saraji A, Stegmann-Frehse J, Kruper R, Schüle R, Pantel K, Taubert H, Duensing S, Culig Z, Aigner A, Klapper W, Jonigk D, Philipp Kühnel M, Merseburger AS, Kirfel J, Sailer V, Perner S (2021). Analysis of tripartite motif (TRIM) family gene expression in prostate cancer bone metastases; Carcinogenesis 42:1475-1484.
Offermann A, Joerg V, Becker F, Roesch MC, Lemster AL, Tharun L, Behrends J, Merseburger AS, Culig Z, Sailer V, Brägelmann J, Kirfel J, Perner S (2022). Inhibition of cyclin-dependent kinase 8/Cyclin-dependent kinase 19 suppresses its pro-oncogenic effects in prostate cancer; Am J Pathol 192:813-823.
Vakhnusheva O, Erb HHH, Bräunig V, Markowitsch SD, Schupp P, Baer PC, Slade KS, Thomas A, Tsaur I, Puhr M, Culig Z, Cinati J Jr., Michaelis M, Efferth T, Haferkamp A, Juengel E (2022). Artesunate inhibits the growth behavior of docetaxel-resistant prostate cancer cells; Front Oncol 12:789284.
Limberger T, Schlederer M, Trachtova K, Garces de Los Fayos Alonso I, Yang J, Högler S, Sternberg C, Bystry V, Oppelt J Tichy B, Schmeidl M, Kodajova P, Jäger A, Neubauer HA, Oberhuber M, Schmalzbauer BS, Pospisilova S, Dolznig H, Wadsak W, Culig Z, Turner SD, Egger G, Lagger S, Kenner L (2022). KMT2c methyltransferse domain regulated INK4A expression suppresses prostate cancer metastasis; Mol Cancer 21:89, 2022.
Lindner AK, Furlan T, Orme JJ, Tulchiner G, Staudacher N, D´Andrea D, Culig Z, Pichler R (2022). HUS1 as a potential therapeutic target in urothelial cancer; J Clin Med 11:2208.
Muresan XM, Slabakova E, Prochazkova J, Drapela S, Fedr R, Pickova M, Vacek O, VIchova R, Suchankova T, Bouchal J, Kurfurstova D, Kral M, Hulinova T, Sykora RP, Student V, Hejret V, van Weerden WM, Puhr M, Pustka V, Potesil D, Zdrahal Z, Culig Z, Soucek K (2022). Toll-like receptor 3 overexpression induces invasion of prostate cancer cells, whereas its activation triggers apoptosis; Am J Pathol 192:1321-1335.
Frantzi M, Heidegger I, Roesch MC, Gomez-Gomez E, Steiner E, Vlahou A, Mullen W, Guler I, Merseburger AS, Mischak H, Culig Z (2022). Validation of diagnostic nomograms based on CE-MS urinary biomarkers to detect clinically significant prostate cancer; World J Urol 40:2195-2203.
Mengual L, Frantzi M, Mokou M, Ingelmo-Torres M, Vlaming M, Merseburger AS, Roesch MC, Culig Z, Alcaraz A, Vlahou A, Mischak H, van der Heijden AG (2022). Multicentric validation of diagnostic tests based on BC-116 and BC-106 urine peptide biomarkers for bladder cancer in two prospective cohorts of patients; Br J Cancer 127:2043-2051.
Frantzi M, Culig Z, Heidegger I, Mokou M, Latosinska A, Roesch MC, Merseburger AS, Makridakis M, Vlahou A, Blanca-Pedregosa A, Carrasco-Valente J, Mischak H, Gomez-Gomez E (2023). Mass spectrometry-based biomarkers to detect prostate cancer: a multicentric study based on non-invasive urine collection without prior digital rectal examination; Cancers (Basel) 15:1166.
Pardella E, Pranzini E, Nesi L, Parri M, Spatafora P, Torre E, Muccilli A, Castiglione F, Fambrini M, Sorbi F, Cirri P, Caselli A, Puhr M, Klocker H, Serni S, Raugei G, Magherini F, Taddei ML (2022). Therapy-induced stromal senescence promoting aggressiveness of prostate and ovarian cancer; Cells 11:4026.
Baier AK, Puhr M, Stope MB, Thomas C, Erb H (2023). Metabolic changes during prostate cancer development and progression; J Cancer Res Clin Oncol 149:2259-2270.
Csizmarik A, Keresztes D, Nagy N, Bracht T, Sitek B, Witzke K, Puhr M, Tomyi I, Lazar J, Takacs L, Kramer G, Sevcenco S, Maj-Hes A, Juranyi Z, Hadaschik B, Nyrady P, Szarvas T (2022): Proteome profiling of enzalutamide-resistant cell lines and serum analysis identified ALCAM as marker of resistance in castration-resistant prostate cancer; Int J Cancer 15:1405-1419.
Kersztes D, Csizmarik A, Nagy N, Modos O, Fazekas T, Bracht T, Sitek B, Witzke K, Puhr M, Sevonico S, Kramer G, Shariat S, Kuronya Z, Takacs L, Tornyi I, Lazar J, Hadaschik B, Laszik A, Szucs M, Nyriady P, Szarvas T (2022). Comparative proteome analysis identified CD44 as a possible serum marker for docetaxel resistance in castration-resistant prostate cancer; J Cell Mol Med 26:1332-1337.
Kalogirou C, LInxweiler J, Schmucker P, Snabjornsson MT, Schmitz W, Wach S, Krebs M, Hartmann E, Puhr M, Müller A, Spahn M, Seitz AK, Frank T, Marouf H, Büchel G, Eckstein M, Kübler H, Eilers M, Saar M, Junker K, Röhrig F, Kneitz B, Rosenfeldt MT, Schulze A (2021). MiR-205-driven downregulation of cholesterol biosynthesis through SQLE-inhibition identifies therapeutic vulnerability in aggressive prostate cancer; Nat Commun 20:5066.
Puhr M, Eigentler A, Handle F, Hackl H, Ploner C, Heidegger I, Schaefer G, Brandt MP, Hoefer J, van der Pluijm G, Klocker H (2021). Targeting the glucocorticoid receptor signature gene Mono Amine Oxidase-A enhances the efficacy of chemo- and anti-androgen therapy in advanced prostate cancer; Oncogene 40:3087-3100.
Kafka M, Gruber R, Neuwirt H, Ladurner M, Eder IE (2022). Long-term treatment with simvastatin leads to reduced migration capacity in prostate cancer cells; Biomedicines 11:29.
Ladurner M, Wieser M, Eigentler A, Seewald M, Dobler G, Neuwirt H, Kafka M, Heidegger I, Horninger W, Bektic J, Klocker H, Obrist P, Eder IE (2023). Validation of cell-free RNA and circulating tumor cells for molecular marker analysis in metastatic prostate cancer; Biomedicines 12:1004.
Kafka M, Mayr F, Temmi V, Möller G, Adamski J, Höfer J, Schwaiger S, Heidegger I, Matusczak B, Schuster D, Klocker H, Bektic J, Stuppner H, Eder IE (2020). Dual inhibitory action of a novel AKR1C3 inhibitor on both full-length AR and the variant AR-V7 in enzalutamide resistant metastatic castration resistant prostate cancer; Cancers (Basel) 12:2092.
Neuwirt H, Bouchal J, Kharashvili G, Ploner C, Jöhrer K, Pitterl F, Weber A, Klocker H, Eder IE (2020). Cancer-associated fibroblasts promote prostate tumor growth and progression through upregulation of cholesterol and steroid biosynthesis; Cell Commun Signal 18:11.